Sigmoid Pharma to Present at the 37th Annual Cowen & Company Healthcare Conference on March 7th 2017
Dublin (Ireland), February 28, 2017 SIGMOID PHARMA LIMITED, a privately-owned pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases using its proprietary SmPill solid oral delivery platform, announced today that Dr. Ivan Coulter, Chief Executive Officer, will present at the 37th Annual Cowen & Co. Healthcare Conference taking place in Boston, Massachusetts March 6-8, 2017.
Presentation Details:
Title: 37th Annual Cowen & Company Healthcare Conference
Date: Tuesday, March 7
Time: 1:30-1:55 PM EST
Location: Falmouth, 4th Floor, The Marriott Copley Hotel, Boston.
About Sigmoid Pharma
Sigmoid Pharma is a private Irish pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases. The Companys Single-Multiple Pill (SmPill) technology is a versatile drug delivery platform for optimizing the formulation of active therapeutic agents to allow targeted release at the site of gastrointestinal disease or modulate systemic exposure. Sigmoids lead pipeline program is CyCol, a colon-targeted, non-systemic formulation of cyclosporine, a powerful immunosuppressant that has demonstrated efficacy comparable to Remicade in off-label use in steroid-refractory acute severe ulcerative colitis (UC). Thus, CyCol offers potential as an efficacious and safe oral treatment of moderate-severe UC. Another pipeline product has received US FDA Orphan Designation for Graft-versus-Host Disease while a further opportunity exists to develop an adjunct opportunity to modulate gastrointestinal immune-related adverse events (GI-irAEs) associated with various immune-oncology (IO) therapies, including checkpoint inhibitors. For additional information please visit: http://www.sigmoidpharma.com
For further information contact:
Leo Toole
Chief Financial Officer
Sigmoid Pharma Ltd,
Blocks 9/10 Nexus UCD, Belfield Office Park,
Beech Hill Road, Dublin 4, D04 V2N9, Ireland.
Phone +353 (0) 1 700 7452
E-mail: info@sigmoidpharma.com
US Investors:
Andrew McDonald Ph.D.
LifeSci Advisors LLC
andrew@lifesciadvisors.com